Domain: Clinical Medicine / Infectious Diseases (ID)
Expert Persona: Senior Clinical Infectious Disease Specialist and Academic Reviewer
Vocabulary and Tone: Professional, evidence-based, clinical, and clinical-stewardship focused.
The ideal group of people to review this topic would be Clinical Infectious Disease Fellows, Attending Physicians, and Hospital Epidemiologists. This material represents a high-level literature review of the latest evidence-based practices and controversies in ID management.
Process Step 2: Summarize (Strict Objectivity)
Abstract:
This episode of the Infectious Disease Puscast (#99) provides a comprehensive review of clinical literature published between January 15 and January 28, 2026. The discussion covers significant findings across viral, bacterial, fungal, and parasitic domains, with a secondary focus on medical policy and education. Key clinical takeaways include the high prevalence of asymptomatic Norovirus shedding in infants, the diagnostic futility of xenodiagnosis for persistent Lyme disease symptoms, and the low yield of repeat blood cultures in febrile neutropenia after the third day.
The episode also highlights intense professional friction between the ATS and IDSA regarding Community-Acquired Pneumonia (CAP) guidelines and antibiotic stewardship. Longitudinal data on uncomplicated appendicitis reveals a nearly 40% recurrence rate within ten years for patients treated solely with antibiotics. Additionally, the podcast addresses the "Long ID" phenomenon in Coccidioidomycosis and Giardiasis, the cost-prohibitive nature of antiparasitic medications in the U.S., and a significant rift between the AAP and federal agencies regarding the 2026 childhood immunization schedule.
Infectious Disease Puscast #99: Clinical Literature Review and Policy Updates
3:03 Norovirus in Early Life: The PREVAIL cohort study found that by age two, 85% of children had experienced Norovirus. Crucially, two-thirds of these infections were asymptomatic, even at high viral loads, suggesting significant silent transmission.
6:53 Xenodiagnosis for Lyme Disease: A prospective study using ticks to detect Borrelia burgdorferi in patients with persistent symptoms post-treatment was terminated for futility. No evidence of ongoing infection was found, suggesting xenodiagnosis is not a viable clinical tool for this population.
10:16 Febrile Neutropenia Blood Cultures: Research indicates that new bloodstream infections are detected in less than 5% of cases after day three of febrile neutropenia. Continuing repeat cultures often leads to false positives and unnecessary Vancomycin use rather than improved clinical outcomes.
15:58 CAP Guideline Controversy: A "fiery" exchange in the literature details the IDSA’s withdrawal of support for ATS CAP guidelines. The conflict centers on whether to prioritize early empiric treatment (pulmonary perspective) or antibiotic stewardship (ID perspective).
18:13 Pediatric C. difficile Management: A survey of pediatric ID physicians shows a shift toward adult-style management, with 75% preferring oral Vancomycin for initial episodes. However, insurance remains a major barrier to using Fidaxomicin in children.
21:02 Long-term Appendicitis Outcomes: The 10-year follow-up of the APPAC trial found that while antibiotic therapy is safe, 37.8% of patients experience histopathologically confirmed recurrence, and the cumulative appendectomy rate reaches 44.3% by a decade.
23:21 Coccidioidomycosis Persistence: Insurance claims data reveal that symptoms like fatigue, dyspnea, and joint pain remain significantly elevated 6 to 12 months post-diagnosis, particularly in women and those with underlying conditions.
25:49 Ocular Candidemia Screening: A retrospective study found ocular candidiasis in only 5% of candidemia patients. While 60% of those with ocular involvement were asymptomatic, the low overall yield continues to fuel the debate between ID and Ophthalmology regarding universal screening.
29:56 Post-infectious Giardiasis: Literature synthesis confirms a "Long Giardia" syndrome, where patients experience irritable bowel syndrome (IBS), chronic fatigue, and cognitive impairment for months or years following infection.
31:20 Antiparasitic Pricing Crisis: The exorbitant cost of drugs like Albendazole and Praziquantel in the U.S. (sometimes exceeding $48,000 for a year’s treatment) creates massive health disparities, as these off-patent drugs remain market-monopolized.
33:41 2026 Immunization Schedule Split: The AAP has released its own 2026 immunization schedule, notably refusing to endorse the CDC/Federal schedule following what is described as a political interference in vaccine recommendations.
36:19 Resident Prescribing Habits: A qualitative study on "feeling the vibes" in residency reveals that trainees often prescribe antibiotics based on institutional culture, fear of deterioration, and attending preference rather than strict guideline adherence.